Huadong Medical Institute of Biotechniques, Nanjing, China.
Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China.
Microbiol Immunol. 2024 Jul;68(7):213-223. doi: 10.1111/1348-0421.13130. Epub 2024 May 15.
Acute kidney injury (AKI) has considerably high morbidity and mortality but we do not have proper treatment for it. There is an urgent need to develop new prevention or treatment methods. Gut microbiota has a close connection with renal diseases and has become the new therapy target for AKI. In this study, we found the oral administration of the probiotic Limosilactobacillus reuteri had a prevention effect on the AKI induced by lipopolysaccharide (LPS). It reduced serum concentration of creatinine and urea nitrogen and protected the renal cells from necrosis and apoptosis. Meanwhile, L. reuteri improved the gut barrier function, which is destroyed in AKI, and modulated the gut microbiota and relevant metabolites. Compared with the LPS group, L. reuteri increased the proportion of Proteobacteria and reduced the proportion of Firmicutes, changing the overall structure of the gut microbiota. It also influenced the fecal metabolites and changed the metabolite pathways, such as tyrosine metabolism, pentose and glucuronate interconversions, galactose metabolism, purine metabolism, and insulin resistance. These results showed that L. reuteri is a potential therapy for AKI as it helps in sustaining the gut barrier integrity and modulating gut microbiota and related metabolites.
急性肾损伤（AKI）的发病率和死亡率相当高，但我们没有适当的治疗方法。因此，迫切需要开发新的预防或治疗方法。肠道微生物群与肾脏疾病密切相关，已成为 AKI 的新治疗靶点。在这项研究中，我们发现口服益生菌罗伊氏乳杆菌（Limosilactobacillus reuteri）对脂多糖（LPS）诱导的 AKI 具有预防作用。它降低了血清肌酐和尿素氮的浓度，保护了肾脏细胞免受坏死和凋亡。同时，L. reuteri 改善了 AKI 中受损的肠道屏障功能，并调节了肠道微生物群和相关代谢物。与 LPS 组相比，L. reuteri 增加了变形菌门的比例，降低了厚壁菌门的比例，改变了肠道微生物群的整体结构。它还影响粪便代谢物并改变代谢途径，如酪氨酸代谢、戊糖和葡萄糖醛酸相互转化、半乳糖代谢、嘌呤代谢和胰岛素抵抗。这些结果表明，L. reuteri 可能是一种治疗 AKI 的潜在方法，因为它有助于维持肠道屏障的完整性，并调节肠道微生物群和相关代谢物。
